Abstract

Cervical cancer screening is rapidly evolving, prioritizing Human Papillomavirus (HPV)-based primary screening and extended intervals. Innovations like HPV self-sampling, Artificial Intelligence (AI) in diagnostics, and telemedicine enhance access and accuracy. The impact of HPV vaccination is recalibrating guidelines. Yet, barriers related to social determinants of health and access persist, particularly in low-income regions. Addressing these through cost-effective strategies, targeted interventions, and improved modalities like co-testing is crucial for equitable global cervical cancer prevention.